NCT06198413 - LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

December 26, 2024

Study Completion Date

January 31, 2029

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

GENETIC

LX102 subretinal injection

LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

Trial Locations (3)

Anhui Provincial Hospital, Hefei

Zhejiang University Eye Hospital, Hangzhou

Shanghai General Hospital, Shanghai